Fibrotic Phenotype of Peritumour Mesenteric Adipose Tissue in Human Colon Cancer: A Potential Hallmark of Metastatic Properties
Tabuso M., Adya R., Stark R., Gopalakrishnan K., Tsang YW., James S.
Prospective Study with a reported sample of 6, published in Int J Mol Sci (2021) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Int J Mol Sci (2021)
- Reported sample size
- 6
- Source database
- Europe PMC
- PMID
- 33670920
- PMCID
- PMC7957668
- DOI
- 10.3390/ijms22052430
- Citations
- 11
Abstract (original English)
The impact of tumour associated stroma on cancer metastasis is an emerging field. However, cancer associated genes in peritumoral adipose tissue (pAT) in human colon cancer have not been explored. The aim of this study was to identify differentially expressed genes (DEGs) associated with cancer pathways in mesenteric pAT compared with adjacent adipose tissue. In total, nine patients with colon cancer pathological stage T2/T4 were employed in this study. DEGs were identified in 6 patients employing Nanostring PanCancer Pathway Panel and pathway enrichment analyses were performed. Differential expression of the 5 most up-regulated and 2 down regulated genes was validated with qRT-PCR. Results showed collagen type I alpha 1 chain ( COL1A1 ) p = 0.007; secreted frizzled related protein ( SFRP2 ) p = 0.057; fibroblast growth factor 7 ( FGF7 ) not significant (ns); phospholipase A2, group IIA ( PLA2G2A ) ns; nerve growth factor receptor ( NGFR ) ns; lymphoid enhancer binding factor 1 ( LEF1 ) p = 0.03; cadherin 1, Type 1, E-cadherin (epithelial) ( CDH1 ) 0.09. Results have highlighted down-regulation of the Wingless/Integrated (Wnt) pathway in mesenteric pAT compared to distal adipose tissue. Highly upregulated genes in mesenteric pAT were involved in extracellular matrix (ECM)-receptor interactions and focal adhesion. Highly down regulated genes were involved in the cell cycle. Immu
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.